Despite India’s enormous technological potential, indigenous medicinal knowledge and various initiatives by the government and industry at translational cycle, the country carries a global disease burden of 21%, majorly contributed by dual disease burden. Public health faces the major anomalies of 3A (accessibility, affordability, availability) of the healthcare sector, possibly due to restrictive coordination among stakeholders, transiting disease profile, undeveloped delivery system and regulatory mechanisms.

Order of the High Court of Delhi in the matter of Nuziveedu Seeds Ltd. And Others Vs Monsanto Technology LLC And Others dated 11/04/2018 regarding Monsanto's appeal for patents on its BT cotton seeds in India. Monsanto claims that the patent is a biotech invention containing the infusion of Bt gene into the cotton genome. The Bt. bacterium eradicates pests afflicting the cotton plant. Monsanto states that the patent does not cover plants per se, but does cover components that can be termed microbiological processes and microorganisms, thus patentable under the Patents Act.

The Indian Council of Medical Research (ICMR) has released the Handbook on Intellectual Property Rights & Technology Transfer which will help increase awareness among ICMR scientists to help them protect all new knowledge before publication.

Judgement of the High Court of Delhi in the matter of Monsanto Technology LLC & Others Vs Nuziveedu Seeds Limited & Others dated 28/03/2017 regarding Nuziveedu Seeds Limited continuing to “market and sell” Genetically Modified Hybrid Cotton Planting Seeds inspite of termination of the sub-license agreements and use of trademarks BOLLGARD and BOLLGARD II.

Delhi High Court dismissed the plea of Monsanto Technology and said that Nuziveedu Seeds Limited are entitled to all the rights under the 2015 Sub License Agreements except as to the rate of trait fee payable thereunder.

India continues to languish near the bottom in an international intellectual property index, ranking 43rd out of 45 global economies, according to a report by the US Chamber of Commerce's Global Intellectual Property Center (GIPC).

Patents and other intellectual property such as know-how are a complex issue for policy makers and civil society experts, especially considering the large number of patents involved and the sensitivity and confidentiality around licensing agreements. This paper does not attempt to offer a solution to the patent debate.

To understand the impediments that IPR poses for a successful phase-down of HFCs in developing countries, Centre for Science and Environment (CSE) and Council for Scientific and Industrial Research-Unit for Research and Development Information Products (CSIR-URDIP) carried out a study of the number and nature of patents filed in India around the

This report provides guidance for countries to enhance the functioning and transparency of the patent system for the timely and affordable access to lifesaving treatment. Affordable access to treatment is closely linked with the aspiration to ensure health and well-being for all, as embodied in the Sustainable Development Goal (SDG).

What are we to do about antibiotic resistance? Last week, another government report repeated stark warnings about the crisis, and offered some suggestions to improve the situation. The UK report, prepared by a panel chaired by the economist Jim O'Neill, naturally focused on financial incentives, including US$1-billion prizes for pharmaceutical firms that develop new antimicrobial drugs.

Original Source

The Union Cabinet approved the National Intellectual Property Rights (IPR) Policy that will lay the future roadmap for intellectual property in India. The Policy recognises the abundance of creative and innovative energies that flow in India, and the need to tap into and channelise these energies towards a better and brighter future for all.

Pages